Therefore, targeting de novo pyrimidine synthesis with DHODH inhibitors disrupts the metabolic and biosynthetic processes, leading to the cytotoxic effects observed in tumor cells reliant on this pathway for survival. The gene discussed is DHODH; the disease is neoplasm.